DE69532279D1 - Methoden und zusammensetzung zur inhibition der angiogenese - Google Patents

Methoden und zusammensetzung zur inhibition der angiogenese

Info

Publication number
DE69532279D1
DE69532279D1 DE69532279T DE69532279T DE69532279D1 DE 69532279 D1 DE69532279 D1 DE 69532279D1 DE 69532279 T DE69532279 T DE 69532279T DE 69532279 T DE69532279 T DE 69532279T DE 69532279 D1 DE69532279 D1 DE 69532279D1
Authority
DE
Germany
Prior art keywords
angiogenesis
inhibition
composition
methods
admin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69532279T
Other languages
English (en)
Other versions
DE69532279T3 (de
DE69532279T2 (de
Inventor
Peter Brooks
David A Cheresh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22783992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69532279(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE69532279D1 publication Critical patent/DE69532279D1/de
Publication of DE69532279T2 publication Critical patent/DE69532279T2/de
Publication of DE69532279T3 publication Critical patent/DE69532279T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69532279T 1994-03-18 1995-03-09 Methoden und zusammensetzung zur inhibition der angiogenese Expired - Lifetime DE69532279T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US210715 1994-03-18
US08/210,715 US5753230A (en) 1994-03-18 1994-03-18 Methods and compositions useful for inhibition of angiogenesis
US08/366,665 US5766591A (en) 1994-03-18 1994-12-30 Methods and compositions useful for inhibition of angiogenesis
US366665 1994-12-30
PCT/US1995/003035 WO1995025543A1 (en) 1994-03-18 1995-03-09 Methods and compositions useful for inhibition of angiogenesis
EP95913644A EP0754059B2 (de) 1994-03-18 1995-03-09 Methoden und zusammensetzung zur inhibition der angiogenese

Publications (3)

Publication Number Publication Date
DE69532279D1 true DE69532279D1 (de) 2004-01-22
DE69532279T2 DE69532279T2 (de) 2004-09-16
DE69532279T3 DE69532279T3 (de) 2011-11-17

Family

ID=22783992

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69532279T Expired - Lifetime DE69532279T3 (de) 1994-03-18 1995-03-09 Methoden und zusammensetzung zur inhibition der angiogenese
DE69536128T Expired - Lifetime DE69536128D1 (de) 1994-03-18 1995-03-09 Methoden und Zusammensetzungen zur Inhibition der Angiogenese

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69536128T Expired - Lifetime DE69536128D1 (de) 1994-03-18 1995-03-09 Methoden und Zusammensetzungen zur Inhibition der Angiogenese

Country Status (25)

Country Link
US (7) US5753230A (de)
EP (3) EP1410807B1 (de)
JP (2) JP4268222B2 (de)
KR (1) KR100327081B1 (de)
CN (1) CN1161152C (de)
AT (3) ATE255907T1 (de)
AU (1) AU709645B2 (de)
CA (1) CA2184493C (de)
CZ (1) CZ294650B6 (de)
DE (2) DE69532279T3 (de)
DK (3) DK1410807T3 (de)
ES (3) ES2355074T3 (de)
FI (1) FI121916B (de)
HK (1) HK1013960A1 (de)
HU (1) HU221988B1 (de)
MX (1) MX9604145A (de)
NO (1) NO322441B1 (de)
NZ (3) NZ511293A (de)
PT (2) PT754059E (de)
RU (1) RU2162712C2 (de)
SI (1) SI0754059T2 (de)
SK (1) SK284586B6 (de)
UA (1) UA44729C2 (de)
WO (1) WO1995025543A1 (de)
ZA (1) ZA952214B (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6949511B1 (en) 1994-04-26 2005-09-27 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
ATE308981T1 (de) * 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
BR9610422A (pt) 1995-08-30 1999-07-13 Searle & Co Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
BR9611174A (pt) * 1995-10-23 1999-09-14 Childrens Medical Center Proteína de endostatina isolada, e composições terapêuticas antiangiogénicas formadas com a mesma.
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
JP4189033B2 (ja) * 1996-08-15 2008-12-03 ノバルティス アクチエンゲゼルシャフト 定量的関節炎状態のアッセイ
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2321991T3 (es) * 1996-12-09 2009-06-15 Merck Patent Gmbh Receptor de adhesion alfavbet3 recombinante soluble.
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
EP1491632A3 (de) * 1997-03-12 2006-01-04 Smithkline Beecham Corporation Anti-alphavbeta3 humanizierte monoklonale Antikörper
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
DE69840046D1 (de) * 1997-03-19 2008-11-06 Lucid Inc Zellchirurgie unter benutzung konfokaler mikroskopie
AU6954498A (en) * 1997-04-11 1998-11-11 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
EP0973550B1 (de) * 1997-04-11 2002-10-09 G.D. SEARLE & CO. Antagonistische anti-avb3 integrin antikörper
US6596276B1 (en) * 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
BR9909420A (pt) 1998-03-31 2001-09-25 Du Pont Pharm Co Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
EP2311490A3 (de) 1998-07-13 2011-05-04 Board of Regents, The University of Texas System Verwendung von Antikörper gegen Aminophospholipide zur Krebsbehandlung
RU2167425C2 (ru) * 1998-07-17 2001-05-20 Малышев Игорь Юрьевич Способ определения белков
US6164281A (en) * 1998-07-20 2000-12-26 Zhao; Iris Ginron Method of making and/or treating diseases characterized by neovascularization
WO2000009143A1 (en) * 1998-08-13 2000-02-24 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US7176289B1 (en) 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6235877B1 (en) 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
ES2242437T3 (es) * 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.
US6339062B1 (en) * 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (de) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Pharmazeutische zusammensetzungen, vitronectinrezeptor antagonisten enthaltend
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035492A2 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7115261B1 (en) * 1999-02-12 2006-10-03 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
AU4187200A (en) * 1999-04-01 2000-10-23 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6685914B1 (en) * 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
AU781442B2 (en) * 1999-09-23 2005-05-26 Scripps Research Institute, The Method and compositions for inhibiting adhesion formation
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
EP1221973B1 (de) * 1999-10-04 2007-05-30 Novartis Vaccines and Diagnostics, Inc. CD40 Antagonist zur Behandlung von Psoriasis
AU781444B2 (en) 1999-12-22 2005-05-26 Scripps Research Institute, The Angiogenesis and vascular permeability modulators and inhibitors
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CA2399001C (en) * 2000-02-03 2010-07-20 Eisai Co., Ltd. Integrin expression inhibitor
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
US20010053766A1 (en) * 2000-02-11 2001-12-20 Janardan Kumar Method of treating disorders of the eye
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6835806B2 (en) 2000-04-03 2004-12-28 Phoenix Pharmaceuticals, Inc. Cell growth regulation system
WO2001077145A2 (en) 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US20040105857A1 (en) * 2000-10-02 2004-06-03 Anthony Montgomery Methods and compositions for enhancing angiogenesis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
DE10109136A1 (de) * 2001-02-26 2002-09-12 Cytotools Gmbh Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren
NZ528076A (en) * 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
ATE510557T1 (de) 2001-04-24 2011-06-15 Merck Patent Gmbh Kombinationstherapie mit antiangiogenen mitteln und tnfalpha
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
AU2002312566A1 (en) * 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
WO2003006491A2 (en) 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
AU2002329643B2 (en) * 2001-07-27 2006-11-16 University Of Kansas Medical Center Crystallized structure of type IV collagen NC1 domain hexamer
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
CA2459584A1 (en) * 2001-09-05 2003-03-13 Cynthia C. Bamdad Compositions and use thereof in the treatment of cancer
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
CN1658894A (zh) * 2002-02-14 2005-08-24 默克专利股份有限公司 用于治疗眼病的方法和组合物
US20050106136A1 (en) * 2002-02-15 2005-05-19 Richard Brunner 7s immunoglobulin for treatment of choroidal neovascularisation
EP1487492A4 (de) * 2002-03-04 2008-10-01 Medimmune Inc Prävention oder behandlung von krebs mit integrin alphavbeta3 antagonisten in kombination mit anderen mitteln
US20050084489A1 (en) * 2002-03-04 2005-04-21 Wilder Ronald L. Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
US20040175378A1 (en) 2002-07-15 2004-09-09 Board Of Regents, The University Of Texas System Selected antibody compositions and methods for binding to aminophospholipids
GB0217018D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 1
KR20050025976A (ko) * 2002-07-23 2005-03-14 더 리젠츠 오브 더 유니버시티 오브 미시건 항-혈관형성 치료법에 사용하기 위한 테트라프로필암모늄테트라티오몰리브데이트 및 관련 화합물
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2004058044A2 (en) 2002-11-19 2004-07-15 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
JP2006516635A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストの使用
EP1594898A2 (de) 2003-02-06 2005-11-16 Tripep AB Glycosylierte spezifitätaustauscher
US7335359B2 (en) * 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP1616009A2 (de) * 2003-04-18 2006-01-18 The University of British Columbia Verfahren zur behandlung von angiogenischen erkrankungen
AU2004265226A1 (en) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
KR20060035608A (ko) * 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
WO2004113361A2 (en) * 2003-06-20 2004-12-29 The Regents Of The University Of California Novel prokineticin receptor isoforms and methods of use
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
KR20190067944A (ko) 2004-01-22 2019-06-17 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
AU2005215017A1 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
DK1755660T3 (da) * 2004-05-07 2010-07-19 Univ North Carolina Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I
US20060286102A1 (en) * 2004-05-14 2006-12-21 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
EP1765362B1 (de) 2004-06-04 2012-03-28 The Scripps Research Institute Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US20060029544A1 (en) * 2004-08-06 2006-02-09 The Regents Of The University Of California Office Of Technology Transfer Receptor-binding cyclic peptides and methods of use
CA2577370A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
EP1831254B1 (de) * 2004-12-23 2012-06-06 Molmed SpA Konjugationsprodukt
US20080317752A1 (en) * 2005-04-18 2008-12-25 Sloan-Kettering Institute For Cancer Research Inhibition of Tumorigenesis by Inhibition of a6b4 Integrin
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20060286148A1 (en) * 2005-05-18 2006-12-21 Ppd, Inc. Method of forming implants
EP1899376A2 (de) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antikörper gegen hmgb 1 und fragmente davon
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2335733B1 (de) 2006-01-18 2014-08-06 Merck Patent GmbH Spezifische Krebsbehandlung mit Integrin-Liganden
KR101201886B1 (ko) 2006-01-19 2012-11-15 아이진 주식회사 펩타이드를 유효성분으로 하는 혈관 관련 질환 치료제 조성물
NZ574093A (en) * 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
WO2008008373A2 (en) 2006-07-11 2008-01-17 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP2441464B1 (de) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin-liganden zur verwendung in der behandlung von darmkrebs
DK2025685T3 (da) * 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
JP5809415B2 (ja) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド 抗ｖｅｇｆ抗体の組成物および方法
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
CA2737146A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
EP2352817B1 (de) 2008-10-31 2016-01-27 University Of Louisville Research Foundation, Inc. Stammzellen aus der riechschleimhaut und ihre verwendung
JP2012513589A (ja) 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド 骨髄イメージング剤としての９９ｍＴｃ−ペプチド系化合物の応用
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
CA2763275A1 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
FR2949782B1 (fr) * 2009-09-04 2015-10-16 Isp Investments Inc Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
CA2805338A1 (en) 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
ES2683347T3 (es) 2011-02-11 2018-09-26 Merck Patent Gmbh Anticuerpo anti-integrina alfa-v para el tratamiento de cáncer de próstata
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
RU2531502C2 (ru) * 2011-08-09 2014-10-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ повышения ангиогенной активности стромальных клеток жировой ткани
RU2481115C1 (ru) * 2011-10-13 2013-05-10 Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
CN104968796A (zh) * 2012-06-07 2015-10-07 庄伟哲 经修饰纤维黏连蛋白片段或变体及其用途
CN104768975A (zh) 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
US9587001B2 (en) 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
JP2016501887A (ja) 2012-12-07 2016-01-21 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ ヒスチジン官能性を有するカチオン性両親媒性化合物およびその製造プロセス、並びにリポソーム製剤
CN105358708A (zh) * 2013-03-14 2016-02-24 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
EP3576726A1 (de) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Verfahren und produkte in verbindung mit glutaminase-hemmern
JP2020512978A (ja) 2017-03-31 2020-04-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法
KR102171433B1 (ko) * 2018-05-25 2020-11-02 고려대학교 산학협력단 조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
CN113557246B (zh) * 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
EP4007579A4 (de) * 2019-08-02 2023-08-09 The Regents of the University of California Zusammensetzungen und verfahren zum abzielen auf und töten von alpha-v beta-3-positiven krebsstammzellen (cscs) und zur behandlung von arzneimittelresistentem und metastatischem krebs
AU2021332460A1 (en) 2020-08-27 2023-04-06 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
JPH02502156A (ja) * 1987-11-19 1990-07-19 スクリップス　クリニック　アンド　リサーチ　ファウンデーション 内皮細胞のｒｇｄ指向粘着レセプターに対するモノクローナル抗体
JPH01169343A (ja) 1987-12-25 1989-07-04 Nippon Sheet Glass Co Ltd ガラス板の切口欠点検出装置
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
DE68910113T2 (de) * 1988-01-19 1994-03-17 Childrens Hospital Corp Wachstuminhibierendes mittel und dessen verwendung.
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5686568A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregration inhibitors
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
EP0470569B1 (de) * 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff
CA2048078A1 (en) * 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
DE69233254T2 (de) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5578704A (en) 1992-04-03 1996-11-26 Genentech, Inc. Antibody to osteoclast alphavbeta3 ntegrin
SK57693A3 (en) * 1992-06-18 1994-07-06 Merck Patent Gmbh Linear peptides and pharmaceutical agents on their base
UA43823C2 (uk) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
ATE250138T1 (de) 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
AU6235294A (en) * 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
CA2175214A1 (en) † 1993-11-05 1995-05-11 Barry S. Coller Platelet-specific chimeric immunoglobulin and methods of use therefor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate

Also Published As

Publication number Publication date
CZ271196A3 (cs) 1998-01-14
ES2211901T3 (es) 2004-07-16
ES2211901T5 (es) 2011-12-12
EP0754059A4 (de) 1997-07-30
EP0754059B2 (de) 2011-08-24
DK1410807T3 (da) 2011-03-07
DE69532279T3 (de) 2011-11-17
SK284586B6 (sk) 2005-07-01
ZA952214B (en) 1996-02-08
KR100327081B1 (ko) 2002-10-18
EP1468695B1 (de) 2011-11-23
UA44729C2 (uk) 2002-03-15
EP1410807A1 (de) 2004-04-21
DK0754059T3 (da) 2004-04-13
HU221988B1 (hu) 2003-03-28
SK119096A3 (en) 1997-07-09
RU2162712C2 (ru) 2001-02-10
NO322441B1 (no) 2006-10-09
US7354586B2 (en) 2008-04-08
FI963692A (fi) 1996-09-18
US7329406B2 (en) 2008-02-12
WO1995025543A1 (en) 1995-09-28
US7482007B2 (en) 2009-01-27
NO963894D0 (no) 1996-09-17
NZ511293A (en) 2005-06-24
JP4268222B2 (ja) 2009-05-27
EP1410807B1 (de) 2010-12-08
JP2006273862A (ja) 2006-10-12
US7595051B2 (en) 2009-09-29
EP0754059A1 (de) 1997-01-22
US5766591A (en) 1998-06-16
US20040265317A1 (en) 2004-12-30
US20040258691A1 (en) 2004-12-23
SI0754059T2 (sl) 2011-12-30
EP1468695A1 (de) 2004-10-20
KR970701564A (ko) 1997-04-12
CN1151120A (zh) 1997-06-04
DE69532279T2 (de) 2004-09-16
CN1161152C (zh) 2004-08-11
HK1013960A1 (en) 1999-09-17
ES2355074T3 (es) 2011-03-22
JP4758281B2 (ja) 2011-08-24
DK1468695T3 (da) 2012-02-27
PT754059E (pt) 2004-04-30
MX9604145A (es) 1998-05-31
ATE255907T1 (de) 2003-12-15
US20080175840A1 (en) 2008-07-24
NZ548433A (en) 2008-04-30
ATE490784T1 (de) 2010-12-15
AU709645B2 (en) 1999-09-02
SI0754059T1 (en) 2004-06-30
ATE534403T1 (de) 2011-12-15
ES2376850T3 (es) 2012-03-20
CA2184493C (en) 2010-05-11
DK0754059T4 (da) 2011-09-19
EP0754059B1 (de) 2003-12-10
HUT76086A (en) 1997-06-30
PT1468695E (pt) 2012-02-09
CA2184493A1 (en) 1995-09-28
FI121916B (fi) 2011-06-15
FI963692A0 (fi) 1996-09-18
DE69536128D1 (de) 2011-01-20
US20050002936A1 (en) 2005-01-06
HU9602541D0 (en) 1996-11-28
US6887473B1 (en) 2005-05-03
NO963894L (no) 1996-11-18
US5753230A (en) 1998-05-19
JPH10500398A (ja) 1998-01-13
AU1995295A (en) 1995-10-09
NZ283022A (en) 2001-05-25
CZ294650B6 (cs) 2005-02-16

Similar Documents

Publication Publication Date Title
DE69532279D1 (de) Methoden und zusammensetzung zur inhibition der angiogenese
DE3673161D1 (de) Renininhibitoren und verfahren zur anwendung derselben.
ATE513908T1 (de) Antiangiogenische polypeptide und verfahren zur angiogenesehemmung
KR960703646A (ko) 게임 장치 및 게임의 리플레이 방법(Game Apparatus and Method of Replaying Game)
AR243728A1 (es) Metodo para producir una composicion humectante de tejidos epiteliales.
DE3881405D1 (de) Antientzuendungsmittel.
NO971568D0 (no) Analoger av keratinocyttvekstfaktor
ATE294187T1 (de) Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung
PL295838A1 (en) Method of renovating railroad tracks and set of machinery therefor
DE59204773D1 (de) Verfahren zur isolierung von rohren
DE59709922D1 (de) Pflaster zur transdermalen anwendung von pergolid
PL319078A1 (en) Method of obtaining pallidipine-modified inhibitor of collagen induced aggregation of thrombocytes
ATE81455T1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
EP0450086A4 (en) Kit for immunoassay of human tissue plasminogen activator/human plasminogen activator inhibitor complex and method of immunoassay
ATE200414T1 (de) Verwendung eines mittels zur haarbehandlung
BG102060A (en) The use of alendronate for osteoporosis prevention
DE69621805T2 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten
DE3780757D1 (de) Antigestagene zur hemmung der uterinen prostaglandinsynthese.
ES2146607T3 (es) Mezcla proteolitica que contiene escarasa y metodo de aislar la misma.
UA27856C2 (uk) Атравматична голка та спосіб її виготовлення
ATA6084A (de) Verfarhen zur oberflaechenpruefung von stahlstraengen sowie einrichtung zur durchfuehrung des verfahrens
ATA26293A (de) Verfahren zur herstellung und anwendung eines gesichtsmikrofonsystems
ATA119496A (de) Verfahren zur verringerung der menge des schmutzkondensats und einrichtung zur durchführung des verfahrens
ITBO940511A0 (it) Simulatore sperimentale per prove invecchiamento accelerato materiali ceramici

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 754059

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 754059

Country of ref document: EP

Effective date: 20110824